Kevin Lee, Bicycle Therapeutics CEO (Bicycle)
July 13, 2021 10:42 AM EDT
Deals

Strug­gling Io­n­is li­cens­es Bi­cy­cle Ther­a­peu­tic­s' plat­form in a bid to de­vel­op drugs that can cross blood-brain bar­ri­er

Max Gelman

Senior Editor

At­tempt­ing to re­bound from set­backs ear­li­er this year, Io­n­is has en­list­ed a new part­ner in a quest to cre­ate drugs that can cross the blood …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times